Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Dec 2020| PHM062D| BCC Publishing
Report Overview

Report Highlights

The global market for Alzheimer's disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.

Report Includes

  • 27 tables
  • An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics
  • Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates
  • Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.
  • Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents
  • Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World
  • Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi

Report Scope

The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (Aβ) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat, i.e., mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesPrice Member Price
Full Report: Alzheimer's Disease Therapeutics and Diagnostics: Global Markets88 $5,500 Free
Chapter- 1: Introduction3Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Overview20$1,279Free
Chapter- 4: Regulatory Structure7$448Free
Chapter- 5: Market Dynamics3$192Free
Chapter- 6: Global Markets for Alzheimer's Disease Therapeutics10$640Free
Chapter- 7: Market Breakdown by Region13$831Free
Chapter- 8: Pipeline Analysis10$640Free
Chapter- 9: Company Profiles18$1,151Free
Chapter- 10: Appendix: Acronyms2$128Free
Published - Mar-2016| Analyst - Ufuk Ezer| Code - PHM062C

Report Highlights

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

Report Includes

  • An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • Review of programs in development and quantification of market opportunities
  • Discussion of the market segments' economic environment, technological descriptions and issues, and applications
  • Projections of usage in the major primary and secondary disease application areas
  • Profiles of major players in the industry

Published - May-2013| Analyst - Yogita Zutshi| Code - PHM062B

Report Highlights

The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.

Report Includes

  • An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
  • Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Review of programs in development and quantification of market opportunities
  • Discussion of the market segments' economic environment, technological descriptions and issues, and applications
  • Projections of usage in the major primary and secondary disease application areas
  • Comprehensive company profiles of major players in the industry.
Published - Jan-2010| Analyst - Maura Warner| Code - PHM062A

Report Highlights

  • Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. This market was worth $8 billion in 2009 and is expected to reach $9.6 billion by 2014, a compound annual growth rate (CAGR) of 3.7%.
  • Diagnostics and biomarkers are expected to increase at a 5-year compound annual growth rate (CAGR) of nearly 20%. This segment was worth $1.2 billion in 2009 and is expected to reach $2.9 billion by 2014.
  • The imaging sector was worth $361 million in 2009 and is expected to increase at a nearly 19% compound annual growth rate (CAGR) to reach $852 million in 2014.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Single User License: $5500

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report